Abstract
The antiepileptic drug valproic acid (VPA) is widely used in the treatment of epilepsy, bipolar disorders, and migraine. However, rather high doses are required for the clinical effects of VPA, which is due to its relatively inefficient delivery to the brain. The poor brain distribution of VPA is thought to reflect an asymmetric transport system at the blood-brain barrier (BBB). Based on recent data from in vitro experiments, multidrug resistance proteins (MRPs) have been proposed to be involved in the efflux transport of VPA at the BBB. In the present study, we used different experimental in vitro and in vivo strategies to evaluate whether VPA is a substrate for MRPs or the efflux transporter P-glycoprotein (Pgp). In contrast to known Pgp or MRP substrates, such as cyclosporin A or vinblastine, no directional transport of VPA was observed in cell monolayer efflux assays using the kidney cell lines Madin Darby canine kidney II and LLC-PK1, which had been transfected with either human or mouse cDNAs for the genes encoding Pgp, MRP1, or MRP2. Likewise, no indication for efflux transport of VPA was obtained in a rat microdialysis model, using inhibitors of either Pgp or MRPs. Furthermore, a significant role of MRP2 in brain efflux of VPA was excluded by using MRP2-deficient rats. Our data do not support the hypothesis that MRP1 or MRP2 is involved in the efflux of VPA from the brain. Thus, the molecular identity of the putative transporter(s) mediating the active efflux of VPA from the brain remains to be elucidated.
Footnotes
-
The study was supported by the Deutsche Forschungsgemeinschaft (Bonn, Germany; Grant Lo 274/9-3) and by Desitin (Hamburg, Germany).
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.106.102491.
-
ABBREVIATIONS: VPA, valproic acid; AED, antiepileptic drug; BBB, blood-brain barrier; CSF, cerebrospinal fluid; MRP, multidrug resistance protein or multidrug resistance-associated protein; ABC, ATP-binding cassette; Pgp, P-glycoprotein; BMEC, bovine brain microvessel endothelial cell; MDCK, Madin Darby canine kidney; MDR, multidrug resistance; TR–, MRP2 deficient; TR, transport ratio; cTR, corrected transport ratio; MK571, (E)-3-[[[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-[[3-dimethylamino)-3-oxopropyl]thio]methyl]thio]-propanoic acid; ANOVA, analysis of variance; AUC, area(s) under the curve; OAT, organic anion transporter; VBL, vinblastine; wt, wild type.
-
↵1 Current affiliation: International Neuroscience Institute, Hannover, Germany
- Received February 6, 2006.
- Accepted October 12, 2006.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|